# Erythroderma: The Red Patient

## Introduction

Erythroderma (exfoliative dermatitis) is defined as erythema and scaling involving at least **90% of the body surface area**. It is a dermatologic emergency that can lead to significant morbidity and mortality through hemodynamic compromise, thermoregulatory failure, and metabolic derangement. Identifying the underlying cause directs therapy and affects prognosis.

## Etiology

### Pre-existing Dermatosis (Most Common -- approximately 50%)

**Psoriasis** is the most common identifiable cause and may be triggered by abrupt withdrawal of systemic corticosteroids, systemic illness, or phototherapy burns. **Atopic dermatitis/eczema**, particularly in the elderly, is another frequent cause. **Contact dermatitis** may generalize from widespread allergen exposure or autosensitization. **Seborrheic dermatitis** rarely progresses to erythroderma. **Pityriasis rubra pilaris (PRP)** classically shows **islands of sparing** within the erythroderma, an orange-red color, and waxy palmoplantar keratoderma.

### Drug Reactions (approximately 25%)

**Common culprits** include sulfonamides, anticonvulsants (phenytoin, carbamazepine, lamotrigine), allopurinol, antibiotics (penicillins, cephalosporins), gold, and dapsone. The eruption may be part of **DRESS syndrome** (Drug Reaction with Eosinophilia and Systemic Symptoms). Onset is typically 2 to 6 weeks after drug initiation, though longer for DRESS.

### Malignancy (approximately 10 to 15%)

**Cutaneous T-cell lymphoma (CTCL)** in its leukemic form is known as Sezary syndrome, characterized by circulating Sezary cells (CD4+ T cells with cerebriform nuclei). Other lymphomas and leukemias, including Hodgkin lymphoma and adult T-cell leukemia/lymphoma (HTLV-1), may present with erythroderma. Solid organ malignancies are rare causes (paraneoplastic erythroderma).

### Idiopathic (approximately 20 to 30%)

No identifiable cause is found despite thorough investigation. Some idiopathic cases may evolve into CTCL over time, making long-term follow-up with repeat biopsies recommended.

| Etiology | Frequency | Key Diagnostic Clues | Treatment Approach |
|----------|-----------|---------------------|-------------------|
| Psoriasis | ~25% | Nail pitting/oil-drop, prior history, thick silvery scale | Cyclosporine, biologics (AVOID systemic steroids) |
| Atopic dermatitis/Eczema | ~20% | Prior atopy, lichenification, facial edema | Short-course steroids, cyclosporine, dupilumab |
| Drug reaction | ~25% | New drug 2–6 wks prior, eosinophilia, DRESS features | Drug withdrawal, systemic corticosteroids |
| CTCL/Sezary syndrome | ~10–15% | Sezary cells, CD4:CD8 >10, clonal TCR | ECP, methotrexate, bexarotene, mogamulizumab |
| PRP | ~5% | Islands of sparing, orange-red hue, waxy PPK | Acitretin, methotrexate, biologics |
| Idiopathic | ~20–30% | Exclusion of all above | Supportive; long-term surveillance for CTCL |

<image>Clinical photograph of a patient with erythroderma showing diffuse erythema and exfoliation affecting greater than 90% of body surface area, with close-up of characteristic lamellar scaling and residual islands of sparing suggestive of pityriasis rubra pilaris</image>

## Pathophysiology and Systemic Complications

### Thermoregulatory Failure

**Loss of vasoregulatory control** with widespread vasodilation leads to increased cutaneous blood flow that may double cardiac output demands. Impaired thermoregulation causes heat loss through convection and evaporation from inflamed skin. **Hypothermia** is common, though paradoxically patients may also develop fever from infection, drug reaction, or lymphoma.

### Hemodynamic Compromise

High-output cardiac failure develops from chronic increased cutaneous blood flow. Peripheral edema results from increased capillary permeability and hypoalbuminemia. **Tachycardia** occurs as a compensatory response.

### Metabolic Derangement

**Protein loss** is massive, with transepidermal protein loss of up to 9 g/m2/day through exfoliative scaling. **Hypoalbuminemia** drives peripheral edema and is worsened by the hepatic acute phase response. **Iron deficiency anemia** results from chronic inflammation and skin loss. **Folate deficiency** occurs from increased epidermal turnover. **Electrolyte imbalances**, particularly calcium and zinc, may develop.

### Infectious Risk

The disrupted skin barrier increases susceptibility to **Staphylococcus aureus** bacteremia and sepsis. Skin colonization with S. aureus is nearly universal in erythroderma, and **sepsis** is a leading cause of mortality.

## Clinical Assessment

### History

The history should focus on **pre-existing skin disease** (history of psoriasis, eczema, or other dermatosis), **medications** (detailed drug history with timeline, focusing on new medications in the preceding 2 to 6 weeks), **constitutional symptoms** (weight loss, night sweats, lymphadenopathy suggesting malignancy), and **pruritus** (intense in eczema and CTCL, variable in psoriasis and drug reactions).

### Physical Examination

**Nail changes** including pitting, oil-drop sign, and onycholysis point to psoriasis. **Hair** shows diffuse alopecia common in erythroderma of any cause. **Palmoplantar involvement** with waxy yellow-orange keratoderma suggests PRP, while fissured hyperkeratosis suggests eczema. **Islands of sparing** (nappes claires) are classic for PRP. **Lymphadenopathy** with generalized reactive (dermatopathic) nodes is common, but persistent firm nodes require biopsy to exclude lymphoma. **Hepatosplenomegaly** suggests lymphoma, DRESS, or secondary hemophagocytic syndrome. **Facial edema and lichenification** occur in chronic atopic erythroderma, and ectropion may develop.

### Investigations

**Skin biopsy** should involve multiple biopsies (at least 2 to 3 from different sites) to increase diagnostic yield, as histology may be obscured by nonspecific changes. Repeat biopsies over time are indicated if initial ones are nondiagnostic. **Blood work** includes CBC with differential (eosinophilia in drug reaction/DRESS, lymphocytosis with Sezary cells in CTCL), comprehensive metabolic panel, albumin, LDH, and uric acid. **Flow cytometry** of peripheral blood for CD4+/CD7- or CD4+/CD26- T cells and a CD4:CD8 ratio greater than 10 suggests Sezary syndrome. **T-cell receptor gene rearrangement** showing clonal TCR rearrangement supports CTCL diagnosis. **Lymph node biopsy** is indicated for persistent lymphadenopathy to distinguish dermatopathic change from lymphoma. **Patch testing** is performed after erythroderma resolves if contact dermatitis is suspected.

<image>Diagnostic algorithm for erythroderma workup: clinical history and exam leading to multiple skin biopsies, peripheral blood flow cytometry, TCR gene rearrangement, complete metabolic panel, and medication review, with branching pathways to pre-existing dermatosis, drug reaction, CTCL/Sezary syndrome, and idiopathic categories</image>

## Management

### Acute Stabilization

**Admission** to hospital is indicated for severe cases with hemodynamic compromise, high-output failure, hypothermia, or infection. **Temperature regulation** with a warm environment and warming blankets addresses thermoregulatory failure. **Fluid and electrolyte replacement** with IV fluids corrects dehydration, and hypoalbuminemia is addressed. **Nutritional support** with a high-protein diet and replacement of folate, iron, and zinc is essential. **Infection surveillance** includes blood cultures if febrile, with a low threshold for empiric anti-staphylococcal antibiotics. **Emollients** should be applied liberally (petrolatum-based), with oatmeal baths and wet wraps providing symptomatic relief.

### Cause-Specific Treatment

**Psoriatic erythroderma** is treated with cyclosporine 3 to 5 mg/kg/day for rapid control, methotrexate, or biologics (infliximab for rapid onset). Systemic corticosteroids should be AVOIDED due to rebound risk. **Eczematous erythroderma** is treated with systemic corticosteroids (short course), cyclosporine, or dupilumab. **Drug-induced** erythroderma requires identification and withdrawal of the offending drug, systemic corticosteroids for DRESS, and monitoring for visceral involvement. **PRP** is treated with acitretin 25 to 50 mg/day, methotrexate, or biologics (TNF inhibitors, IL-17/23 inhibitors with growing evidence). **Sezary syndrome/erythrodermic CTCL** is managed with extracorporeal photopheresis (ECP), low-dose methotrexate, bexarotene, mogamulizumab (anti-CCR4), interferon-alpha, and total skin electron beam therapy.

### Medications to Avoid

**Systemic corticosteroids in psoriatic erythroderma** carry risk of severe rebound flare and pustular transformation upon taper. **Phototherapy** is contraindicated during acute erythroderma due to Koebner phenomenon and burn risk.

## Prognosis

**Mortality** is 10 to 20% in hospitalized patients, primarily from sepsis, cardiac failure, or progression of underlying malignancy. **Idiopathic erythroderma** may persist chronically, and up to 10 to 15% may evolve into CTCL, warranting surveillance with repeat biopsies.

## Key Clinical Pearls

Erythroderma is a dermatologic emergency requiring prioritization of hemodynamic stabilization, temperature regulation, and infection prevention. Multiple skin biopsies from different sites increase diagnostic yield, as a single biopsy is often nondiagnostic. Islands of sparing within erythroderma strongly suggest pityriasis rubra pilaris. Systemic corticosteroids must be avoided in psoriatic erythroderma, with cyclosporine or biologics used instead to prevent rebound. Idiopathic erythroderma requires long-term follow-up with repeat biopsies to monitor for evolution to CTCL.

## References

1. Sigurdsson V, Steegmans PH, van Vloten WA. The incidence of erythroderma: a survey among all dermatologists in the Netherlands. *J Am Acad Dermatol*. 2001;45(5):675-678.
2. Rothe MJ, Bernstein ML, Grant-Kels JM. Life-threatening erythroderma: diagnosing and treating the "red man." *Clin Dermatol*. 2005;23(2):206-217.
3. Cuellar-Barboza A, Ocampo-Candiani J, Herz-Ruelas ME. A practical approach to the diagnosis and treatment of adult erythroderma. *Actas Dermosifiliogr*. 2018;109(9):777-790.
4. Li J, Zheng HY. Erythroderma: a clinical and prognostic study. *Dermatology*. 2012;225(2):154-162.